IRIS
COSTANZO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.985
AS - Asia 8.497
EU - Europa 2.509
SA - Sud America 1.660
AF - Africa 353
Continente sconosciuto - Info sul continente non disponibili 294
OC - Oceania 28
AN - Antartide 1
Totale 27.327
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.648
SG - Singapore 5.247
CN - Cina 1.455
BR - Brasile 1.373
VN - Vietnam 815
IT - Italia 581
FI - Finlandia 376
IE - Irlanda 331
DE - Germania 243
HK - Hong Kong 234
NG - Nigeria 225
FR - Francia 195
GB - Regno Unito 188
CA - Canada 186
IN - India 165
NL - Olanda 126
AR - Argentina 109
BD - Bangladesh 100
MX - Messico 80
TR - Turchia 72
SE - Svezia 67
RU - Federazione Russa 57
BE - Belgio 53
EC - Ecuador 53
ES - Italia 53
IQ - Iraq 50
ID - Indonesia 45
UA - Ucraina 44
ZA - Sudafrica 43
PK - Pakistan 40
PL - Polonia 39
JP - Giappone 34
IL - Israele 28
CL - Cile 25
VE - Venezuela 24
CO - Colombia 21
PE - Perù 21
AU - Australia 20
JO - Giordania 19
CZ - Repubblica Ceca 18
SA - Arabia Saudita 18
UZ - Uzbekistan 18
PH - Filippine 17
JM - Giamaica 16
PY - Paraguay 16
RO - Romania 16
GR - Grecia 15
MY - Malesia 15
EG - Egitto 14
TN - Tunisia 14
AE - Emirati Arabi Uniti 12
CH - Svizzera 12
DO - Repubblica Dominicana 12
KR - Corea 12
A2 - ???statistics.table.value.countryCode.A2??? 11
AZ - Azerbaigian 11
LT - Lituania 11
MA - Marocco 11
NP - Nepal 11
AL - Albania 10
DZ - Algeria 10
HU - Ungheria 10
OM - Oman 10
KE - Kenya 9
TH - Thailandia 9
UY - Uruguay 9
AT - Austria 8
ET - Etiopia 8
KZ - Kazakistan 8
RS - Serbia 8
NZ - Nuova Zelanda 7
PA - Panama 7
DK - Danimarca 6
HN - Honduras 6
IR - Iran 6
KG - Kirghizistan 6
PS - Palestinian Territory 6
PT - Portogallo 6
BG - Bulgaria 5
MD - Moldavia 5
NI - Nicaragua 5
NO - Norvegia 5
SN - Senegal 5
TT - Trinidad e Tobago 5
XK - ???statistics.table.value.countryCode.XK??? 5
AO - Angola 4
BO - Bolivia 4
CR - Costa Rica 4
LB - Libano 4
LV - Lettonia 4
LY - Libia 4
SK - Slovacchia (Repubblica Slovacca) 4
TW - Taiwan 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
BN - Brunei Darussalam 3
EU - Europa 3
KH - Cambogia 3
KW - Kuwait 3
PR - Porto Rico 3
Totale 27.002
Salva come PNG Salva come JPEG
Città #
Singapore 2.228
Chandler 1.695
Wilmington 1.450
Ashburn 1.137
The Dalles 730
Shanghai 678
San Jose 671
San Mateo 575
Dallas 505
Ann Arbor 454
Council Bluffs 454
Helsinki 373
Boardman 356
Dublin 329
New York 314
Beijing 304
Ho Chi Minh City 298
Princeton 266
Lawrence 262
Leawood 259
Benin City 223
Hong Kong 216
Milan 214
Los Angeles 191
Hanoi 184
Santa Clara 178
Fairfield 146
Paris 138
Woodbridge 134
São Paulo 125
Amsterdam 99
London 78
Seattle 74
Toronto 72
Buffalo 71
Phoenix 65
Rome 65
Brussels 50
Chicago 48
Orem 46
San Diego 45
Belo Horizonte 41
Rio de Janeiro 37
Brooklyn 36
Houston 36
Chennai 35
Haiphong 34
Falls Church 33
Da Nang 30
Atlanta 29
Tokyo 29
Warsaw 29
Charlotte 28
Kocaeli 28
Montreal 28
Falkenstein 27
San Francisco 27
Johannesburg 26
Manchester 26
Figino 25
Norwalk 25
Columbus 21
Mexico City 21
Frankfurt am Main 19
Munich 19
Guarulhos 18
Queens 18
Amman 17
Boston 17
Hải Dương 17
Lima 17
Tashkent 17
Campinas 16
Curitiba 16
Goiânia 16
Las Vegas 16
Quito 16
Redmond 16
Dhaka 15
Guayaquil 15
Moscow 15
Philadelphia 15
Salvador 15
Baghdad 14
Can Tho 14
Miami 14
Naples 14
New Delhi 14
Cleveland 13
Detroit 13
Istanbul 13
Lahore 13
Porto Alegre 13
Sorocaba 13
Stockholm 13
Assago 12
Buenos Aires 12
Fortaleza 12
Pasadena 12
Poplar 12
Totale 17.002
Salva come PNG Salva come JPEG
Nome #
Living with Chronic Spontaneous Urticaria in Italy: A Narrative Medicine Project to Improve the Pathway of Patient Care 334
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study 291
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 204
y Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis 154
CD28 costimulation regulates FOXP3 in a RelA/NF-κB-dependent mechanism. 154
Brodalumab: a new way to inhibit IL-17 in psoriasis 127
A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias 127
Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics 125
Upadacitinib improves symptoms of concomitant allergic rhinitis or allergic asthma in patients with severe atopic dermatitis: A 16-week multicentre retrospective study 120
DNA Methylation Signature in Monozygotic Twins Discordant for Psoriatic Disease 120
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial 120
Actinic keratosis treated with an immune response modifier: a case report of six patients 118
IL-21 in the pathogenesis and treatment of skin diseases. 117
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study 117
Chronic Hand Eczema (CHE): A Narrative Review 116
Rosacea-like Acute Reaction After Hyaluronic Acid Dermal Filler 114
A role of p73 in mitotic exit 114
'Living with chronic urticaria': a study through narrative medicine to improve the quality of care 114
FGF8, c-Abl and p300 participate in a pathway that controls stability and function of the Delta Np63 alpha protein 112
A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis 112
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) 110
Herpes simplex virus disrupts NF-kappa B regulation by blocking its recruitment on the I kappa B alpha promoter and directing the factor on viral genes 109
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 109
Psoriasis: from pathogenesis to novel therapeutic approaches. 108
Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis 107
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. 107
How to make a skin-tight dress: the p63/claudin-1 connection 106
A p38-dependent pathway regulates DNp63 DNA binding to p53 dependent promoters in UV-induced apoptosis of keratinocytes 106
A symphony of regulations centered on p63 to control development of ectoderm-derived structures. 106
Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway 106
A feedback regulatory loop between p63 and Dlx3: implications for epidermal differentiation 104
A p38-dependent pathway regulates Delta Np63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes 103
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis) 103
Infliximab in psoriasis and psoriatic arthritis. 101
A role for the p63-IKKalpha pathway in the development of ectodermal dysplasias 101
Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients 101
p63-dependent and independent mechanisms of nectin-1 and -4 regulation in the epidermis. 100
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 100
A myogenic differentiation checkpoint activated by genotoxic stress 99
p63 induces key target genes required for epidermal morphogenesis 98
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris. 97
Noninferiority of biosimilar MSB110222 to reference adalimumab for chronic plaque psoriasis 97
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 97
p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis 96
Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA) 96
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 95
Adalimumab for severe psoriasis and psoriatic arthritis: an open label study in 30 patients previously treated with other biologics 95
The p53/p63/p73 family of transcription factors: overlapping and distinct functions. . 2000 May;113 ( Pt 10):1661-70 94
Programmed cell death in the skin 94
Cutaneous and Mucosal Manifestations of Sjögren’s Syndrome 94
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 94
CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappa B subunits on IL-8 and Bcl-xL gene promotors 93
Zosteriform metastasis of occult bronchogenic carcinoma. 93
Efalizumab 93
Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology. 1997 Oct;113(4):1384-9 93
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 93
No metagenomic evidence of tumorigenic viruses in cancers from a selected cohort of immunosuppressed subjects 92
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 92
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis 92
Role of the HLA-C(star)06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients 91
Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome. 91
Topical use of valproic acid for the prevention or treatment of skin disorders 91
The tumor suppressor activity of IKK alpha in stratified epithelia is exerted in part via the TGF-beta anti proliferative pathway 90
Treatment of psoriasis and psoriatic arthritis. 89
Living Matter Observations with a Novel Hyperspectral Supercontinuum Confocal Microscope for VIS to Near-IR Reflectance Spectroscopy 89
HLA‐C*06 and psoriasis: susceptibility, phenotype, course and response to treatment 89
Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta 89
High-dose intravenous immunoglobulin for severe drug reactions: Efficacy in toxic epidermal necrolysis 89
Frontal Fibrosing Alopecia Associated With Oral Erosive Lichen Planus: Two Locations, One Disease 88
IKKalpha downregulation in psoriasis: New insights in the pathway regulating keratinocyte proliferation 88
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 88
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 88
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target. 87
Disease-related and drug-induced skin manifestations in inflammatory bowel disease 87
c-E10 is a caspase-recruiting domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-kappaB 87
Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling 87
Patient-relevant needs and treatment goals in nail psoriasis. 87
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naive patients 87
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 87
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 86
Two new p73 splice variants, gamma and delta, with different transcriptional activity 86
The p73 gene is an anti-tumoral target of the RAR beta/gamma-selective retinoid tazarotene 86
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope 86
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 86
Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. 86
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 86
TRIM8 and p53: making the right decision. 85
Keratosis punctata palmoplantaris and malignancies: Case report 85
DLX5, FGF8 and the Pin1 isomerase control ΔNp63α protein stability during limb development: a regulatory loop at the basis of the SHFM and EEC congenital malformations. 85
Prevalence and genomic variability of transfusion transmitted virus in Italian cryptogenic chronic liver disease and healthy blood donors. 85
Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study) 85
p73 is regulated by phosphorylation at the G2/M transition 84
Role of p63 in keratinocyte differentiation and proliferation 84
Vav cooperates with CD28 to induce NF-kappa B activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1 84
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. 84
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 83
Delta Np63 knockdown mice: a mouse model for AEC syndrome 83
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 83
Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. 83
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 82
Totale 10.330
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.855
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.855
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.423 0 12 19 323 21 38 57 195 143 111 413 91
2022/20234.235 595 166 374 543 399 390 5 353 790 319 242 59
2023/20242.627 158 237 592 68 54 222 174 416 44 54 211 397
2024/20254.124 107 80 45 64 66 427 260 396 571 981 533 594
2025/202610.645 1.598 688 662 999 392 426 3.116 519 549 591 407 698
2026/20271.549 727 822 0 0 0 0 0 0 0 0 0 0
Totale 27.327